Lyophilized Injectable Drugs to 2024

  • ID: 4395406
  • Report
  • 105 Pages
  • Greystone Associates
1 of 4

FEATURED COMPANIES

  • B. Braun
  • Baxter
  • Becton Dickinson
  • Hospira (Pfizer)
  • Schott
  • SHL Medical
  • MORE

The inherent instability of protein drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed - a requirement referred to as the ‘cold chain’. Alternatively, proteins can be formulated as powders (lyophilization). Lyophilized proteins must be reconstituted prior to injection. Lyophilized drugs are sold with reconstitution vial systems, or packaged in special injection devices (e.g., pens, needle-free injectors, two-part syringes) that allow reconstitution to take place in the device prior to injection.

What You Will Learn

  • Provides detailed analysis of lyophilized drugs, as-supplied packaging and therapeutic indication
  • Analyzes therapeutic demand drivers and evaluates lyophilized drugs in eleven therapeutic areas
  • Analyzes lyophilization technologies and market development issues
  • Provides market data and forecasts to 2024
  • Profiles market participants, their product development activities, business strategies, and corporate alliances and affiliations
  • Assesses the importance of technology and regulatory factors on commercialization and market access.

Report Value Chain - Who Should Read this Report

Development

  • Drug Developers
  • Device Suppliers
  • CMOs
  • Components/APIs
  • Testing/Validation
  • Clinical Trial Mgmt

Industry

  • Pharma Managers
  • Biotech Managers
  • Drug Marketers
  • Industry Strategists
  • Financial Analysts
  • Management Consultants

Market

  • Clinical Managers
  • Drug Distributors
  • Pharma Regulators
  • FDA Consultants
  • Managed Care Managers
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • B. Braun
  • Baxter
  • Becton Dickinson
  • Hospira (Pfizer)
  • Schott
  • SHL Medical
  • MORE

Executive Summary

The Market Opportunity

Delivery Market Dynamics

  • The Economics of lyophilized Drugs
  • What’s Driving the Market for Lyophilized Drugs?
  • The Trend toward Self-Administration
  • Shifting Demographics
  • Innovation in Disposable Device Designs
  • Therapeutic Demand Drivers
  • Competitive Landscape
  • Risk Factors

Lyophilized Drugs - Primary Packaging

  • Single Use Vials
  • Point-of-Care Reconstitution
  • Specialty Packaging
  • Drugs for SC/IM Injection
  • Drugs for Infusion
  • Product Specific Devices

Lyophilized Drugs - Reconstitution and Delivery

  • Prefilled Diluent Syringes
  • Proprietary Reconstitution Devices
  • Single Step Devices
  • Multi-Step Devices
  • Human Engineering/Ergonomics

Lyophilized Drugs - Key Therapeutic Sector Analysis and Market Data

  • Antibiotics
  • Autoimmune Diseases
  • Blood Factors
  • Hormones
  • Infectious Diseases
  • Metabolic Conditions
  • Oncology
  • Reproductive Health
  • Other Important Therapeutic Classes

Market Factors

  • Regulatory Issues
  • Patient Compliance and Ease of Use
  • Healthcare Economics

Company Profiles

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • B. Braun
  • Baxter
  • Becton Dickinson
  • Hospira (Pfizer)
  • SHL Medical
  • Schott
  • Vetter
  • Ypsomed
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll